These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2335849)

  • 1. Effects of a thromboxane A2 synthetase inhibitor on ventricular fibrillation threshold during coronary artery occlusion and reperfusion.
    Toda I; Nozaki A; Kawakubo K; Murakawa Y; Inoue H; Yoshimoto N; Sugimoto T
    Jpn Heart J; 1990 Jan; 31(1):87-97. PubMed ID: 2335849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of a novel thromboxane synthetase inhibitor, CV-4151, on myocardial damage due to coronary occlusion and reperfusion in the hearts of anesthetized dogs.
    Imamoto T; Terashita Z; Tanabe M; Nishikawa K; Hirata M
    J Cardiovasc Pharmacol; 1986; 8(4):832-9. PubMed ID: 2427826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death.
    Kitzen JM; Lynch JJ; Uprichard AC; Venkatesh N; Lucchesi BR
    Pharmacology; 1988; 37(3):171-86. PubMed ID: 3227051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
    Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
    J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion.
    O'Connor KM; Friehling TD; Kelliher GJ; MacNab MW; Wetstein L; Kowey PR
    Am Heart J; 1986 Apr; 111(4):683-8. PubMed ID: 3953390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further evidence that thromboxane exacerbates arrhythmias: effects of UK38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds.
    Coker SJ
    J Mol Cell Cardiol; 1984 Jul; 16(7):633-41. PubMed ID: 6433026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion.
    Austin JC; Berrizbeitia LD; Schoen FJ; Kauffman RP; Hechtman HB; Cohn LH
    Am Heart J; 1988 Mar; 115(3):505-9. PubMed ID: 3344655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a thromboxane synthetase inhibitor, Y-20811, on infarct size, neutrophil accumulation, and arrhythmias after coronary artery occlusion and reperfusion in dogs.
    Sato N; Endo T; Kiuchi K; Hayakawa H
    J Cardiovasc Pharmacol; 1993 Mar; 21(3):353-61. PubMed ID: 7681494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between the severity of myocardial ischaemia, reperfusion-induced ventricular fibrillation, and the late administration of dazmegrel or nifedipine.
    Coker SJ; Parratt JR
    J Cardiovasc Pharmacol; 1985; 7(2):327-34. PubMed ID: 2581088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dazoxiben on arrhythmias and ventricular fibrillation induced by coronary artery occlusion and reperfusion in anaesthetised greyhounds.
    Coker SJ; Parratt JR
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):87S-95S. PubMed ID: 6681710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of DP-1904, a new thromboxane A2 synthetase inhibitor, on guinea pig experimental asthma.
    Takami M; Takata Y; Matsumoto K; Ono S; Tsukada W
    Ann N Y Acad Sci; 1991; 629():407-9. PubMed ID: 1952565
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of Y-20811, a thromboxane A2 synthetase inhibitor, on experimentally induced coronary thrombosis in anesthetized dogs.
    Matsumoto Y; Ochi H; Aihara K; Inui J; Ikegami K
    Eur J Pharmacol; 1992 Mar; 213(2):167-70. PubMed ID: 1521557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of thromboxane A2 synthetase failed to limit myocardial infarct size in a rabbit ischemia-reperfusion model.
    Tsuchida A; Miura T; Ogawa T; Iwamoto T; Shimamoto K; Iimura O
    Jpn Circ J; 1991 Feb; 55(2):174-83. PubMed ID: 2020088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries.
    Bush LR; Campbell WB; Buja LM; Tilton GD; Willerson JT
    Circulation; 1984 Jun; 69(6):1161-70. PubMed ID: 6546902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of ventricular fibrillation threshold in infarcted and non-infacted myocardium after acute coronary ligation.
    Roland JM; Dashkoff N; Varghese PJ; Pitt B
    Am Heart J; 1977 Sep; 94(3):336-40. PubMed ID: 888767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of endogenous prostacyclin and thromboxane A2 in the ischemic canine heart.
    Sakai K; Ito K; Ogawa K
    J Cardiovasc Pharmacol; 1982; 4(1):129-35. PubMed ID: 6176788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of timolol on arrhythmias and prostanoid release during canine myocardial ischaemia and reperfusion.
    Coker SJ; Parratt JR
    Br J Pharmacol; 1984 Apr; 81(4):675-84. PubMed ID: 6547068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of nafazatrom in an acute occlusion-reperfusion model of canine myocardial injury.
    Fiedler VB; Mardin M; Perzborn E; Grützmann R
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):267-74. PubMed ID: 3841382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of carbocromene on ventricular fibrillation during acute myocardial ischemia in anesthetized dogs.
    Fiedler VB; Schneider S; Nitz RE
    Pharmacology; 1982; 25(2):96-101. PubMed ID: 7134263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.